Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Gatza, Michael L., Hsiu-Ni Kung, Kimberly L. Blackwell, Mark W. Dewhirst, Jeffrey R. Marks, and Jen-Tsan Chi. “Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes..” Breast Cancer Res 13, no. 3 (June 7, 2011). https://doi.org/10.1186/bcr2899.

PMID
21672245
Full Text

Morse, Michael A., Angeles A. Secord, Kimberly Blackwell, Amy C. Hobeika, Gomathinayagam Sinnathamby, Takuya Osada, Julie Hafner, et al. “MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer..” Clin Cancer Res 17, no. 10 (May 15, 2011): 3408–19. https://doi.org/10.1158/1078-0432.CCR-10-2614.

PMID
21300761
Full Text

Anders, Carey K., Cheng Fan, Joel S. Parker, Lisa A. Carey, Kimberly L. Blackwell, Nancy Klauber-DeMore, and Charles M. Perou. “Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?.” J Clin Oncol 29, no. 1 (January 1, 2011): e18–20. https://doi.org/10.1200/JCO.2010.28.9199.

PMID
21115855
Full Text

Adamo, Barbara, Allison M. Deal, Emily Burrows, Joseph Geradts, Erika Hamilton, Kimberly L. Blackwell, Chad Livasy, et al. “Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases..” Breast Cancer Res 13, no. 6 (2011). https://doi.org/10.1186/bcr3071.

PMID
22132754
Full Text

Hamilton, Erika P., and Kimberly L. Blackwell. “Safety of bevacizumab in patients with metastatic breast cancer..” Oncology 80, no. 5–6 (2011): 314–25. https://doi.org/10.1159/000328757.

PMID
21778772
Full Text

Hamilton, E. P., and K. L. Blackwell. “Third-generation aromatase inhibitors: Differences between the agents and their role in reducing the risk of distant metastasis and improving survival.” European Journal of Clinical and Medical Oncology 2, no. 4 (December 1, 2010).

Scholars@Duke

Mouridsen, Henning T., Per Lønning, Matthias W. Beckmann, Kimberly Blackwell, Julie Doughty, Joseph Gligorov, Antonio Llombart-Cussac, Andre Robidoux, Beat Thürlimann, and Michael Gnant. “Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer..” Expert Rev Anticancer Ther 10, no. 11 (November 2010): 1825–36. https://doi.org/10.1586/era.10.160.

PMID
20883112
Full Text

Russell, Stuart D., Kimberly L. Blackwell, Julia Lawrence, John E. Pippen, Matthew T. Roe, Freda Wood, Virginia Paton, Eric Holmgren, and Kenneth W. Mahaffey. “Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials..” J Clin Oncol 28, no. 21 (July 20, 2010): 3416–21. https://doi.org/10.1200/JCO.2009.23.6950.

PMID
20530275
Full Text

Blackwell, Kimberly L., Harold J. Burstein, Anna Maria Storniolo, Hope Rugo, George Sledge, Maria Koehler, Catherine Ellis, et al. “Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer..” J Clin Oncol 28, no. 7 (March 1, 2010): 1124–30. https://doi.org/10.1200/JCO.2008.21.4437.

PMID
20124187
Full Text

Pages